Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster

Clinical Infectious Diseases

Volumn 45, Issue 10, 2007, Pages 1343-1346

  Arias, Cesar A ^a,c   Torres, Harrys A ^a,b   Singh, Kavindra V ^a   Panesso, Diana ^c   Moore, Judson ^a   Wanger, Audrey ^a   Murray, Barbara E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSIDAD EL BOSQUE   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; DAPTOMYCIN; GENTAMICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; LIGASE; UNCLASSIFIED DRUG; VANA LIGASE, BACTERIA;

ADULT; ANAMNESIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CASE REPORT; DIABETES MELLITUS; DISEASE PREDISPOSITION; DIZZINESS; DOSE RESPONSE; DRUG WITHDRAWAL; ENDOCARDITIS; ENTEROCOCCUS FAECIUM; FOLLOW UP; GENE CLUSTER; GENE LOSS; HUMAN; IN VIVO STUDY; LABORATORY TEST; MALE; MITRAL VALVE REGURGITATION; MONOTHERAPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT REFUSAL; VANA GENE; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; DRUG COMBINATION; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MULTIGENE FAMILY;

AMPICILLIN; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CARBON-OXYGEN LIGASES; DAPTOMYCIN; DNA, BACTERIAL; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECIUM; GENTAMICINS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIGENE FAMILY; TREATMENT FAILURE; VANCOMYCIN RESISTANCE;

EID: 36048945506     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522656     Document Type: Article

References (12)

1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.
2. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007; 54:567-71.
3. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 2006; 58:1208-14.
4. Lewis JS II, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005; 49:1664-5.
5. Alam MR, Donabedian S, Brown W, et al. Heteroresistance to vancomycin in Enterococcus faecium. J Clin Microbiol 2001; 39:3379-81.
6. CLSI. Performance standard for antimicrobial susceptibility testing: 15th informational supplement. CLSI document M100-S15. Wayne, PA: CLSI, 2005.
7. Murray BE, Singh KV, Ross RP, Heath JD, Dunny GM,Weinstock GM. Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function. J Bacteriol 1993; 175:5216-23.
8. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995; 33:1434.
9. Jevitt LA, Thorne GM, Traczewski MM, et al. Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. J Clin Microbiol 2006; 44:3098-104.
10. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581-5.
11. Caron F, Kitzis MD, Gutmann L, et al. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother 1992; 36:2611-6.
12. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342:710-21.